Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: A meta-analysis

Psychiatry Research

Volumn 215, Issue 3, 2014, Pages 505-513

  Shi, Chuan ^a,b,c,d   Yu, Xin ^c,d   Cheung, Eric F C ^e   Shum, David H K ^f   Chan, Raymond C K ^a,b  

^a INSTITUTE OF PSYCHOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^d PEKING UNIVERSITY   (China)

^e CASTLE PEAK HOSPITAL   (Hong Kong)

^f GRIFFITH UNIVERSITY   (Australia)

Author keywords

Intervention; Meta analysis; Negative symptoms; Repetitive transcranial magnetic stimulation; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE DURATION; EFFECT SIZE; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; MOTOR THRESHOLD; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PERCEPTIVE THRESHOLD; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; ADULT; COMPLICATION; DEFENSE MECHANISM; MALE; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY;

ADULT; HUMANS; MALE; NEGATIVISM; PREFRONTAL CORTEX; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84900283431     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.12.019     Document Type: Review

References (73)

1. Alphs L.D., Summerfelt A., Lann H., Muller R.J. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacology Bulletin 1989, 25:159-163.
2. Alvarez-Jimenez M., Gleeson J.F., Henry L.P., Harrigan S.M., Harris M.G., Killackey E., Bendall S., Amminger G.P., Yung A.R., Herrman H., Jackson H.J., McGorry P.D. Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychological Medicine 2012, 42:595-606.
3. American Psychiatric Association, 1980,1987, 1994, 2000. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Third Edition-Revision, Fourth Edition, Fourth Edition-Text Revision. American Psychiatric Association, Washington, DC.
4. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Archives of General Psychiatry 1982, 39:784-788.
5. Andreasen, N.C., 1989. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations. The British journal of Psychiatry. Supplement, 49-58.
6. *).
7. Blanchard J.J., Cohen A.S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophrenia Bulletin 2006, 32:238-245.
8. Boonstra N., Klaassen R., Sytema S., Marshall M., De Haan L., Wunderink L., Wiersma D. Duration of untreated psychosis and negative symptoms-a systematic review and meta-analysis of individual patient data. Schizophrenia Research 2012, 142:12-19.
9. Borenstein M., Hedges L., Higgins J., Rothstein H. Comprehensive Meta-analysis 2005, Biostat, Inc., Englewood NJ.
10. Brune M., Schaub D., Juckel G., Langdon R. Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology. Psychiatry Research 2011, 190:9-17.
11. Brunoni A.R., Lopes M., Kaptchuk T.J., Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PloS One 2009, 4:e4824.
12. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W., Schizophrenia Patient Outcomes Research, T. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010, 36:71-93.
13. Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., David A.S., Lucey J.V., Kerwin R.W. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. The American Journal of Psychiatry 1997, 154:56-63.
14. Cahn W., Rais M., Stigter F.P., van Haren N.E., Caspers E., Hulshoff Pol H.E., Xu Z., Schnack H.G., Kahn R.S. Psychosis and brain volume changes during the first five years of schizophrenia. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2009, 19:147-151.
15. Cho S.S., Strafella A.P. rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PloS One 2009, 4:e6725.
16. *).
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, L. Erlbaum Associates, Hillsdale, N.J. 2nd ed.
18. *).
19. de Jesus D.R., Gil A., Barbosa L., Lobato M.I., Magalhaes P.V., Favalli G.P., Marcolin M.A., Daskalakis Z.J., Belmonte-de-Abreu Pda S. A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research 2011, 188:203-207.
20. Dlabac-de Lange J.J., Knegtering R., Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. The Journal of Clinical Psychiatry 2010, 71:411-418.
21. Eisenegger C., Treyer V., Fehr E., Knoch D. Time-course of "off-line" prefrontal rTMS effects-a PET study. NeuroImage 2008, 42:379-384.
22. Erhart S.M., Marder S.R., Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophrenia Bulletin 2006, 32:234-237.
23. Findling R.L., Robb A., Nyilas M., Forbes R.A., Jin N., Ivanova S., Marcus R., McQuade R.D., Iwamoto T., Carson W.H. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American Journal of Psychiatry 2008, 165:1432-1441.
24. *).
25. Freitas C., Fregni F., Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophrenia Research 2009, 108:11-24.
26. Gonzalez-Blanch C., Perez-Iglesias R., Pardo-Garcia G., Rodriguez-Sanchez J.M., Martinez-Garcia O., Vazquez-Barquero J.L., Crespo-Facorro B. Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia. Psychological Medicine 2010, 40:935-944.
27. Gorecka J.E., Czernikiewicz A. [The relationship between quality of life of schizophrenic patients and clinical parameters of psychosis]. Wiadomosci Lekarskie 2004, 57:408-412.
28. *).
29. *).
30. Hill K., Mann L., Laws K.R., Stephenson C.M., Nimmo-Smith I., McKenna P.J. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatrica Scandinavica 2004, 110:243-256.
31. *).
32. Horan W.P., Kring A.M., Gur R.E., Reise S.P., Blanchard J.J. Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophrenia Research 2011, 132:140-145.
33. Hovington C.L., Bodnar M., Joober R., Malla A.K., Lepage M. Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 2012, 12:224.
34. Huber T.J., Schneider U., Rollnik J. Gender differences in the effect of repetitive transcranial magnetic stimulation in schizophrenia. Psychiatry Research 2003, 120:103-105.
35. Jaeger J., Czobor P., Berns S.M. Basic neuropsychological dimensions in schizophrenia. Schizophrenia Research 2003, 65:105-116.
36. *).
37. Jin Y., Potkin S.G., Kemp A.S., Huerta S.T., Alva G., Thai T.M., Carreon D., Bunney W.E. Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (alphaTMS) on the negative symptoms of schizophrenia. Schizophrenia Bulletin 2006, 32:556-561.
38. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
39. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Research 1989, 30:119-123.
40. *).
41. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry 2009, 14:429-447.
42. Levine S.Z., Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 2010, 36:624-632.
43. Malla A.K., Norman R.M., McLean T.S., MacDonald C., McIntosh E., Dean-Lashley F., Lynch J., Scholten D., Ahmed R. Determinants of quality of life in first-episode psychosis. Acta Psychiatrica Scandinavica 2004, 109:46-54.
44. *).
45. Moller H.J. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003, 17:793-823.
46. Moller H.J. Clinical evaluation of negative symptoms in schizophrenia. European Psychiatry: The Journal of the Association of European Psychiatrists 2007, 22:380-386.
47. *).
48. Oh S.Y., Kim Y.K. Adjunctive treatment of bimodal repetitive transcranial magnetic stimulation (rTMS) in pharmacologically non-responsive patients with schizophrenia: a preliminary study. Progress in Neuro-psychopharmacology and Biological Psychiatry 2011, 35:1938-1943.
49. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biological Psychiatry 2011, 70:88-96.
50. Pell G.S., Roth Y., Zangen A. Modulation of cortical excitability induced by repetitive transcranial magnetic stimulation: influence of timing and geometrical parameters and underlying mechanisms. Progress in Neurobiology 2011, 93:59-98.
51. Peralta V., Cuesta M.J. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Research 1994, 53:31-40.
52. *).
53. *).
54. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophrenia Research 2012, 137:147-150.
55. Remington G., Agid O., Foussias G. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Expert Review of Neurotherapeutics 2011, 11:589-607.
56. Rollnik J.D., Huber T.J., Mogk H., Siggelkow S., Kropp S., Dengler R., Emrich H.M., Schneider U. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport 2000, 11:4013-4015.
57. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychological Bulletin 1979, 86:638-641.
58. Rossi S., Hallett M., Rossini P.M., Pascual-Leone A., Safety of T.M.S.C.G. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology 2009, 120:2008-2039.
59. Rossini P.M., Barker A.T., Berardelli A., Caramia M.D., Caruso G., Cracco R.Q., Dimitrijevic M.R., Hallett M., Katayama Y., Lucking C.H., et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalography and Clinical Neurophysiology 1994, 91:79-92.
60. *).
61. *).
62. Salimi K., Jarskog L.F., Lieberman J.A. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 2009, 23:837-855.
63. *).
64. Semkovska M., Bedard M.A., Stip E. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives]. L'Encephale 2001, 27:405-415.
65. Shamsi S., Lau A., Lencz T., Burdick K.E., DeRosse P., Brenner R., Lindenmayer J.P., Malhotra A.K. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophrenia Research 2011, 126:257-264.
66. Slotema C.W., Blom J.D., Hoek H.W., Sommer I.E. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. The Journal of Clinical Psychiatry 2010, 71:873-884.
67. Stanford A.D., Corcoran C., Bulow P., Bellovin-Weiss S., Malaspina D., Lisanby S.H. High-frequency prefrontal repetitive transcranial magnetic stimulation for the negative symptoms of schizophrenia: a case series. The Journal of ECT 2011, 27:11-17.
68. Trippe J., Mix A., Aydin-Abidin S., Funke K., Benali A. theta burst and conventional low-frequency rTMS differentially affect GABAergic neurotransmission in the rat cortex. Experimental Brain Research. Experimentelle Hirnforschung. Experimentation Cerebrale 2009, 199:411-421.
69. Villalta-Gil V., Vilaplana M., Ochoa S., Haro J.M., Dolz M., Usall J., Cervilla J., Group N. Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients?. Schizophrenia Research 2006, 87:246-253.
70. Walker E.F., Cornblatt B.A., Addington J., Cadenhead K.S., Cannon T.D., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M.T., Woods S.W., Heinssen R. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophrenia Research 2009, 115:50-57.
71. Wang Z., Xue Z., Pu W., Yang B., Li L., Yi W., Wang P., Liu C., Wu G., Liu Z., Rosenheck R.A. Comparison of first-episode and chronic patients diagnosed with schizophrenia: symptoms and childhood trauma. Early Intervention in Psychiatry 2013, 7:23-30.
72. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Archives of General Psychiatry 1988, 45:609-615.
73. World Health Organization, 1978, 1993. The International Classification of Mental and Behavioural Disorders: Diagnostic Research Criteria (9th and 10th rev.). World Health Organization, Geneva.